Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Nonlinear Pharmacokinetics: Overview01:19

Nonlinear Pharmacokinetics: Overview

Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.

Antioxidants (Basel, Switzerland)·2026
Same author

Venetoclax and hypomethylating agents synergize to increase cell death and metabolic remodeling in acute B-lymphoblastic leukemia cells.

Molecular metabolism·2026
Same author

Rapid quantification method of pharmaceuticals in urban wastewater using UHPLC-Orbitrap mass spectrometry-a multi-target approach for EU-directive advanced treatment evaluation.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

THC and CBD Induce Heme Oxygenase-1-Dependent Cell Death and Trigger Mitochondrial Dysfunction in Human Melanoma and Cutaneous Squamous Cell Carcinoma Cells.

Antioxidants (Basel, Switzerland)·2026
Same author

Quality of Life and Chemosensory Function in Post-COVID Patients: Adherence to Olfactory Training.

The Annals of otology, rhinology, and laryngology·2025
Same author

Schmerz (Berlin, Germany)·2025
Same journal

Going beyond cycling versus swapping for treatment sequencing in psoriatic arthritis.

Nature reviews. Rheumatology·2026
Same journal

Targeting P2X7R on synovial fibroblasts to treat refractory RA.

Nature reviews. Rheumatology·2026
Same journal

Obexelimab reduces the risk of IgG4-RD flare.

Nature reviews. Rheumatology·2026
Same journal

Dapirolizumab pegol improves SLE disease activity in phase III trial.

Nature reviews. Rheumatology·2026
Same journal

Dysfunctional UBA1-mutated myeloid cells promote inflammation in VEXAS syndrome.

Nature reviews. Rheumatology·2026
Same journal

Targeting ferroptosis resistance in RA fibroblast-like synoviocytes.

Nature reviews. Rheumatology·2026
See all related articles

Related Experiment Video

Updated: Jun 9, 2026

Intracranial Pharmacotherapy and Pain Assays in Rodents
02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

Using pharmacokinetic principles to optimize pain therapy.

Kay Brune1, Bertold Renner, Burkhard Hinz

  • 1Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nuremberg, Erlangen, Germany.

Nature Reviews. Rheumatology
|September 8, 2010
PubMed
Summary
This summary is machine-generated.

Cyclo-oxygenase (COX) inhibitors manage pain by blocking prostaglandin production. Understanding their pharmacokinetics is crucial for effective pain relief and minimizing adverse drug reactions.

More Related Videos

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
09:38

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

Published on: April 14, 2016

Optimizing Photoneuromodulation Techniques to Evaluate the Role of Green Light-Emitting Diodes in Pain Management
09:03

Optimizing Photoneuromodulation Techniques to Evaluate the Role of Green Light-Emitting Diodes in Pain Management

Published on: March 28, 2025

Related Experiment Videos

Last Updated: Jun 9, 2026

Intracranial Pharmacotherapy and Pain Assays in Rodents
02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
09:38

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

Published on: April 14, 2016

Optimizing Photoneuromodulation Techniques to Evaluate the Role of Green Light-Emitting Diodes in Pain Management
09:03

Optimizing Photoneuromodulation Techniques to Evaluate the Role of Green Light-Emitting Diodes in Pain Management

Published on: March 28, 2025

Area of Science:

  • Pharmacology
  • Biochemistry

Background:

  • Cyclo-oxygenase (COX) inhibitors are essential for managing musculoskeletal pain.
  • These drugs inhibit COX enzymes, reducing prostaglandin (PG) production at inflammatory sites.

Purpose of the Study:

  • To review the pharmacokinetics of widely used COX inhibitors.
  • To explore how drug pharmacokinetics influence analgesic efficacy and adverse drug reactions (ADRs).

Main Methods:

  • Review of existing literature on COX inhibitor pharmacokinetics.
  • Analysis of pharmacokinetic-pharmacodynamic relationships.

Main Results:

  • Drug absorption, distribution, and elimination critically affect pain relief and ADRs.
  • Optimizing COX inhibitor selection requires pharmacokinetic-pharmacodynamic analysis to balance efficacy and safety.

Conclusions:

  • Tailoring COX inhibitor choice based on pharmacokinetic profiles is key to maximizing therapeutic benefits.
  • Minimizing under/overdosing through appropriate pharmacokinetic understanding reduces treatment failure and ADRs.